All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the European School of Haematology (ESH) 2nd How to Diagnose and Treat: Acute Leukaemia meeting, the AML Hub spoke to Jorge E. Cortes, Augusta University, Augusta, US. We asked, How do I treat older patients with AML?
How do I treat older patients with AML?
Jorge E. Cortes describes the changing definitions and classifications of 'older' and 'fit' patients. He discusses factors that could inform treatment choices, such as fragility and comorbidities. He talks about notable drug schema available for this patient population: venetoclax combinations and low dose cytarabine. He details the study design and patient characteristics, and the responses of patients who received these regimens.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox